2月12日，威高血净跌0.10%，成交额5795.79万元。两融数据显示，当日威高血净获融资买入额602.23 万元，融资偿还671.91万元，融资净买入-69.68万元。截至2月12日，威高血净融资融券余额合计1.17亿 元。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 融资方面，威高血净当日融资买入602.23万元。当前融资余额1.16亿元，占流通市值的7.24%。 截至9月30日，威高血净股东户数2.48万，较上期减少20.95%；人均流通股1535股，较上期增加 26.51%。2025年1月-9月，威高血净实现营业收入27.36亿元，同比增长3.45%；归母净利润3.41亿元，同 比增长7.92%。 分红方面，威高血净A股上市后累计派现6582.13万元。 融券方面，威高血净2月12日融券偿还700.00股，融券卖出600.00股，按当日收盘价计算，卖出金额2.45 万元；融券余量8900.00股，融券余额36.28万元。 ...

Group 1 - The core viewpoint of the news is that Weigao Blood Purification has shown a slight increase in stock price and has reported its financial performance, indicating growth in revenue and net profit [1][2]. - As of February 9, Weigao Blood Purification's stock price increased by 0.47%, with a trading volume of 36.10 million yuan. The financing buy-in amount was 5.05 million yuan, while the financing repayment was 7.37 million yuan, resulting in a net financing buy of -2.32 million yuan [1]. - The total balance of margin trading for Weigao Blood Purification as of February 9 is 120 million yuan, which accounts for 7.56% of its circulating market value [1]. Group 2 - As of September 30, the number of shareholders for Weigao Blood Purification is 24,800, a decrease of 20.95% from the previous period. The average circulating shares per person increased by 26.51% to 1,535 shares [2]. - For the period from January to September 2025, Weigao Blood Purification achieved an operating income of 2.736 billion yuan, representing a year-on-year growth of 3.45%. The net profit attributable to the parent company was 341 million yuan, with a year-on-year increase of 7.92% [2]. - Since its A-share listing, Weigao Blood Purification has distributed a total of 65.82 million yuan in dividends [3].

Group 1 - The core viewpoint of the news is that Weigao Blood Purification has shown a slight decline in stock price while maintaining a stable financing balance and positive revenue growth [1][2]. - As of February 6, Weigao Blood Purification's stock price decreased by 0.69%, with a trading volume of 33.35 million yuan. The net financing purchase on that day was 1.54 million yuan, with a total financing and securities balance of 123 million yuan [1]. - The company reported a revenue of 2.736 billion yuan for the period from January to September 2025, reflecting a year-on-year growth of 3.45%, and a net profit attributable to shareholders of 341 million yuan, which is a 7.92% increase year-on-year [2]. Group 2 - The company has a significant portion of its revenue coming from consumables, accounting for 77.55%, while equipment contributes 18.25%, and other sources make up 2.35% and 1.85% respectively [1]. - As of September 30, the number of shareholders for Weigao Blood Purification was 24,800, a decrease of 20.95% from the previous period, while the average circulating shares per person increased by 26.51% to 1,535 shares [2]. - Since its A-share listing, Weigao Blood Purification has distributed a total of 65.82 million yuan in dividends [3].

Group 1 - The core viewpoint of the news is that Weigao Blood Purification has shown positive financial performance with a slight increase in stock price and notable trading activity on January 21, 2025 [1] - On January 21, 2025, Weigao Blood Purification's stock price increased by 1.24%, with a trading volume of 107 million yuan, and a net financing purchase of 1.71 million yuan [1] - As of January 21, 2025, the total balance of margin trading for Weigao Blood Purification is 133 million yuan, which accounts for 8.08% of its market capitalization [1] Group 2 - As of September 30, 2025, the number of shareholders for Weigao Blood Purification is 24,800, a decrease of 20.95% from the previous period, while the average circulating shares per person increased by 26.51% to 1,535 shares [2] - For the period from January to September 2025, Weigao Blood Purification achieved an operating income of 2.736 billion yuan, representing a year-on-year growth of 3.45%, and a net profit attributable to shareholders of 341 million yuan, with a year-on-year increase of 7.92% [2] - Since its A-share listing, Weigao Blood Purification has distributed a total of 65.8213 million yuan in dividends [3]

Core Viewpoint - The company, Weigao Blood Purification, has shown a slight increase in stock price and has reported its financial activities, including financing and revenue growth, indicating a stable performance in the blood purification industry [1][2]. Financing Summary - On January 19, Weigao Blood Purification had a financing buy amount of 6.1682 million yuan, with a net financing buy of 78,900 yuan after repayments [1][2]. - The current financing balance stands at 129 million yuan, accounting for 7.96% of the circulating market value [2]. Stock and Shareholder Information - As of September 30, the number of shareholders for Weigao Blood Purification is 24,800, which is a decrease of 20.95% compared to the previous period [2]. - The average circulating shares per person increased by 26.51% to 1,535 shares [2]. Revenue and Profit Performance - For the period from January to September 2025, Weigao Blood Purification achieved an operating income of 2.736 billion yuan, reflecting a year-on-year growth of 3.45% [2]. - The net profit attributable to the parent company was 341 million yuan, representing a year-on-year increase of 7.92% [2]. Dividend Information - Weigao Blood Purification has cumulatively distributed dividends amounting to 65.8213 million yuan since its A-share listing [3].

Group 1 - The core viewpoint of the news is that Weigao Blood Purification experienced a decline in stock price and trading volume on January 7, with a net financing purchase reported [1] - On January 7, Weigao Blood Purification had a financing buy amount of 18.35 million yuan, with a net financing purchase of 2.26 million yuan, and a total financing and securities balance of 146 million yuan [1][2] - The company reported a revenue of 2.736 billion yuan for the first nine months of 2025, representing a year-on-year growth of 3.45%, and a net profit of 341 million yuan, which is a 7.92% increase year-on-year [2] Group 2 - The company has a main business revenue composition of 77.55% from consumables, 18.25% from equipment, and 2.35% from other sources [2] - As of September 30, the number of shareholders for Weigao Blood Purification was 24,800, a decrease of 20.95% from the previous period, while the average circulating shares per person increased by 26.51% to 1,535 shares [2] - The company has distributed a total of 65.82 million yuan in dividends since its A-share listing [3]

Core Viewpoint - The stock of Weigao Blood Purification experienced a decline of 2.00% on January 7, 2025, with a trading price of 41.14 yuan per share and a market capitalization of 17.186 billion yuan. The company has shown a year-to-date stock price increase of 3.81% and a recent five-day increase of 2.49% [1]. Group 1: Financial Performance - For the period from January to September 2025, Weigao Blood Purification achieved a revenue of 2.736 billion yuan, representing a year-on-year growth of 3.45%. The net profit attributable to shareholders was 341 million yuan, reflecting a year-on-year increase of 7.92% [2]. - The company has distributed a total of 65.8213 million yuan in dividends since its A-share listing [3]. Group 2: Stock and Market Activity - As of January 7, 2025, the stock's trading volume was 76.4939 million yuan, with a turnover rate of 4.70%. The net outflow of main funds was 5.7063 million yuan, with large orders accounting for 16.12% of purchases and 23.57% of sales [1]. - The number of shareholders decreased by 20.95% to 24,800, while the average circulating shares per person increased by 26.51% to 1,535 shares [2]. Group 3: Company Overview - Weigao Blood Purification, established on December 27, 2004, is located in Weihai, Shandong Province. The company specializes in the research, production, and sales of blood purification medical products. Its revenue composition includes consumables (77.55%), equipment (18.25%), and other categories (4.20%) [1].

Core Viewpoint - Weigao Co., Ltd. is undergoing a significant restructuring by exchanging its subsidiary Weigao Purui for shares in Weigao Blood Purification, which will enhance its control and optimize asset allocation, aiming for long-term growth and strategic focus in the healthcare sector [1][2][3] Group 1: Transaction Details - The total transaction price for the asset swap is 8.511 billion yuan, with a price-to-earnings (PE) ratio of 14.66 times based on Weigao Purui's projected net profit for 2024 [1][2] - Weigao Co., Ltd. will increase its stake in Weigao Blood Purification from 23.5% to 52.0%, achieving controlling interest [1][2] - The share price for the new issuance is set at 31.29 yuan, which is approximately 20% lower than Weigao Blood Purification's market price of around 42 yuan at the time of the announcement, providing additional value to Weigao Co., Ltd. shareholders [2] Group 2: Market Position and Growth Potential - Weigao Blood Purification is a leading player in the blood purification market, with a comprehensive product line and sales to over 6,000 medical institutions in China, including more than 1,000 tertiary hospitals [3][4] - The number of hemodialysis patients in China is projected to reach 1.027 million by the end of 2024, reflecting a growth rate of 24%, indicating a robust market for blood purification treatments [4] - The global chronic kidney disease patient population is estimated at 788 million, with China having the highest number, suggesting a growing demand for blood purification services [3][4] Group 3: Strategic Implications - The restructuring is a critical step for Weigao Group to optimize its core assets and enhance its financial performance, including revenue and profit metrics [5] - The integration of Weigao Blood Purification will allow Weigao Co., Ltd. to strengthen its business segments, including single-use medical devices and orthopedic medical devices, creating a clearer operational structure [5] - The company aims to explore new growth opportunities in the biopharmaceutical upstream market, leveraging its existing technologies and market presence [6][7]

12月18日，威高血净跌0.34%，成交额7645.06万元。两融数据显示，当日威高血净获融资买入额 1243.42万元，融资偿还1072.02万元，融资净买入171.40万元。截至12月18日，威高血净融资融券余额 合计1.40亿元。 融资方面，威高血净当日融资买入1243.42万元。当前融资余额1.40亿元，占流通市值的8.68%。 融券方面，威高血净12月18日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量100.00股，融券余额4096.00元。 资料显示，山东威高血液净化制品股份有限公司位于山东省威海火炬高技术产业开发区威高西路7号， 成立日期2004年12月27日，上市日期2025年5月19日，公司主营业务涉及血液净化医用制品的研发、生 产和销售。主营业务收入构成为：耗材类77.55%，设备类18.25%，其他(补充)2.35%，其他1.85%。 截至9月30日，威高血净股东户数2.48万，较上期减少20.95%；人均流通股1535股，较上期增加 26.51%。2025年1月-9月，威高血净实现营业收入27.36亿元，同比增长3.45%；归母净利润3.41 ...

资料显示，山东威高血液净化制品股份有限公司位于山东省威海火炬高技术产业开发区威高西路7号， 成立日期2004年12月27日，上市日期2025年5月19日，公司主营业务涉及血液净化医用制品的研发、生 产和销售。主营业务收入构成为：耗材类77.55%，设备类18.25%，其他(补充)2.35%，其他1.85%。 12月1日，威高血净涨2.00%，成交额1.17亿元。两融数据显示，当日威高血净获融资买入额1226.45万 元，融资偿还1273.81万元，融资净买入-47.36万元。截至12月1日，威高血净融资融券余额合计1.53亿 元。 融资方面，威高血净当日融资买入1226.45万元。当前融资余额1.53亿元，占流通市值的9.42%。 融券方面，威高血净12月1日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元。 责任编辑：小浪快报 截至9月30日，威高血净股东户数2.48万，较上期减少20.95%；人均流通股1535股，较上期增加 26.51%。2025年1月-9月，威高血净实现营业收入27.36亿元，同比增长3.45%；归母净利润3.41亿 ...